{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:03Z","timestamp":1791357063687,"version":"4.3.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.clinthera.2006.10.016","type":"journal-article","created":{"date-parts":[[2006,12,6]],"date-time":"2006-12-06T12:11:17Z","timestamp":1165407077000},"page":"1540-1555","source":"Crossref","is-referenced-by-count":92,"title":["Ramelteon for the treatment of insomnia"],"prefix":"10.1016","volume":"28","author":[{"given":"Nancy L.","family":"Borja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.10.016_bib1","author":"National Sleep Foundation (NSF)"},{"key":"10.1016\/j.clinthera.2006.10.016_bib2","article-title":"Task Force on DSM-IV","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.clinthera.2006.10.016_bib3","series-title":"NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults","author":"National Institutes of Health (NIH) Consensus Development Program","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.016_bib4","first-page":"146","article-title":"Ramelteon: A novel melatonin receptor agonist for the treatment of insomnia","volume":"40","author":"Nguyen","year":"2005","journal-title":"Formulary"},{"key":"10.1016\/j.clinthera.2006.10.016_bib5","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/S0140-6736(04)17480-1","article-title":"Insomnia","volume":"364","author":"Sateia","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2006.10.016_bib6","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00023210-200519120-00007","article-title":"Ramelteon","volume":"19","author":"McGechan","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2006.10.016_bib7","first-page":"114","article-title":"TAK-375 Takeda","volume":"6","author":"Cajochen","year":"2005","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2006.10.016_bib8","series-title":"Rozerem (ramelteon) [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.neuropharm.2004.09.007","article-title":"Neurochemical properties of ramelteon (TAK-375), a selective MT1\/MT2 receptor agonist","volume":"48","author":"Kato","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2006.10.016_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMcp043762","article-title":"Clinical practice. Chronic insomnia","volume":"353","author":"Silber","year":"2005","journal-title":"N Engl J Med"},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2006.10.016_bib11","first-page":"18","article-title":"Therapeutic options in the treatment of insomnia","volume":"66","author":"Erman","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.10.016_bib12","series-title":"Essential Psychopharmacology: Neuroscientific Basis and Practical Applications","author":"Stahl","year":"2000"},{"key":"10.1016\/j.clinthera.2006.10.016_bib13","series-title":"ASHP Midyear Clinical Meeting Symposium Highlights. New and Emerging Agents for Managing Insomnia","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib14","series-title":"Basic 6-Clinical Pharmacology","article-title":"Sedative-hypnotic drugs","author":"Trevor","year":"2003"},{"key":"10.1016\/j.clinthera.2006.10.016_bib15","series-title":"Ambien (zolpidem tartrate) [package insert]","year":"2004"},{"key":"10.1016\/j.clinthera.2006.10.016_bib16","series-title":"Ambien CR(zolpidem tartrate) [package insert]","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.016_bib17","series-title":"Sonata (zaleplon) [package insert]","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.016_bib18","series-title":"Lunesta (eszopiclone) [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib19_1","series-title":"Drug Topics Red Book, 2006","first-page":"232","article-title":"Rx Product listings","author":"Hogge","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.016_bib19_2","series-title":"Drug Topics Red Book, 2006","first-page":"509","article-title":"Rx Product listings","author":"Hogge","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.016_bib19_3","series-title":"Drug Topics Red Book, 2006","first-page":"639","article-title":"Rx Product listings","author":"Hogge","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.016_bib19_4","series-title":"Drug Topics Red Book, 2006","first-page":"656","article-title":"Rx Product listings","author":"Hogge","year":"2006"},{"issue":"Suppl 16","key":"10.1016\/j.clinthera.2006.10.016_bib20","first-page":"41","article-title":"Pharmacologic management of insomnia","volume":"65","author":"Walsh","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.10.016_bib21","doi-asserted-by":"crossref","first-page":"101","DOI":"10.7861\/clinmedicine.5-2-101","article-title":"Assessment and management of insomnia","volume":"5","author":"Wilson","year":"2005","journal-title":"Clin Med"},{"key":"10.1016\/j.clinthera.2006.10.016_bib22","series-title":"Melatonin Monograph [Natural Medicines Comprehensive Database]","author":"Jellin","year":"2006"},{"key":"10.1016\/j.clinthera.2006.10.016_bib23","series-title":"How does Rozerem work [Rozerem Web site]?","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib24","series-title":"Rozerem (ramelteon): The sleepwake cycle [Rozerem Web site]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib25","series-title":"Takeda Pharmaceuticals. Takeda submits new drug application for ramelteon, an investigational sleep drug [Takeda Web site]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib26","series-title":"Syllabus and Scientific Proceedings in Summary Form, 156th Annual Meeting of the American Psychiatric Association","article-title":"TAK-375 is a highly selective agonist at the ML-1 receptor","author":"Hirai","year":"2003"},{"key":"10.1016\/j.clinthera.2006.10.016_bib27","first-page":"A79","article-title":"TAK-375 and its metabolites are selective agonists at MLsls receptors","volume":"26","author":"Hirai","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib28","first-page":"A79","article-title":"TAK-375 and its active metabolite: Lack of binding to non-ML receptor binding sites","volume":"26","author":"Miyamoto","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib29","series-title":"American Psychiatric Association (APA). Syllabus and Scientific Proceedings in Summary Form, 156th Annual Meeting of the American Psychiatric Association","article-title":"Selectivity of the ML -1 agonist TAK375: Lack of binding to non-ML-1 targets","author":"Miyamoto","year":"2003"},{"key":"10.1016\/j.clinthera.2006.10.016_bib30","series-title":"Takeda Pharmaceuticals. Takeda Pharmaceuticals shares early stage data on sleep compound, TAK-375 [Takeda Web site]","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib31","doi-asserted-by":"crossref","first-page":"P22","DOI":"10.1016\/j.clpt.2003.11.084","article-title":"Study of the absorption, metabolism, and excretion of (14C) ramelteon (TAK-375)","volume":"75","author":"Stevenson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.10.016_bib32","first-page":"A54","article-title":"A phase-I open-label study of the absorption, metabolism, and excretion of (14C) ramelteon (TAK-375) following a single oral dose in healthy male subjects","volume":"27","author":"Hibberd","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib33","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2165\/00126839-200506030-00008","article-title":"Ramelteon: TAK 375","volume":"6","year":"2005","journal-title":"Drugs R D"},{"key":"10.1016\/j.clinthera.2006.10.016_bib34","series-title":"Syllabus and Scientific Proceedings in Summary Form, 156th Annual Meeting of the American Psychiatric Association","article-title":"Safety, pharmacokinetics, and pharmacodynamics ofTAK-375 in healthy adults","author":"Stubbs","year":"2003"},{"key":"10.1016\/j.clinthera.2006.10.016_bib35","first-page":"A76","article-title":"A safety, tolerance, and pharmacokinetic study of five single doses of TAK-375 in healthy adults","volume":"26","author":"Stubbs","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib36","doi-asserted-by":"crossref","first-page":"P22","DOI":"10.1016\/j.clpt.2003.11.085","article-title":"Study to investigate the absolute bioavailability of a single oral dose of ramelteon (TAK-375) in healthy male subjects","volume":"75","author":"Stevenson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2006.10.016_bib37","first-page":"A54","article-title":"A phase I study to investigate the absolute bioavailabiliry of a single oral dose of ramelteon (TAK 375) in healthy male subjects","volume":"27","author":"Amakye","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib38","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/0091270005283461","article-title":"Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia","volume":"46","author":"Karim","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.016_bib39","first-page":"1210","article-title":"Effect of food on the systemic exposure of ramelteon (TAK-375) follow ing a single dose","volume":"44","author":"Karim","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.016_bib40","first-page":"A81","article-title":"Age and gender effects on the pharmacokinetics of TAK-375","volume":"26","author":"Greenblatt","year":"2003","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib41","article-title":"Effect of age and gender on the pharmacokinetics of ramelteon (TAK-375), a novel selective ML-1 receptor agonist","author":"Greenblatt","year":"2004"},{"key":"10.1016\/j.clinthera.2006.10.016_bib42","first-page":"1210","article-title":"Single and multiple dose pharmacokinetic evaluation of ramelteon (TAK-375) in subjects with and without hepatic impairment","volume":"44","author":"Karim","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.016_bib43","first-page":"1210","article-title":"Evaluation of the single and multiple dose pharmacokinetics of ramelteon (TAK-375) in subjects with and without renal impairment","volume":"44","author":"Tolbert","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.016_bib44","first-page":"303","article-title":"Ramelteon (TAK-375), a selective MT1\/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment","volume":"28","author":"Roth","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib45","series-title":"Proceedings of the New Clinical Drug Evaluation Unit","article-title":"Phase III studyto determine the efficacyoframelteon in elderly patientswith chronic insomnia","author":"Roth","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.sleep.2005.09.004","article-title":"An efficacy, safety, and closeresponse study of ramelteon in pa tients with chronic primary insomnia","volume":"7","author":"Erman","year":"2006","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2006.10.016_bib47","first-page":"A228","article-title":"Double-blind, placebo-controlled polysomnography and outpatient trial to evaluate the efficacy and safety of ramelteon in adult patients with chronic insomnia","volume":"28","author":"Zammit","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib48","first-page":"A228","article-title":"Double-blind, placebo-controlled outpatient clinical trial of ramelteon for the treatment of chronic insomnia in an elderly population","volume":"28","author":"Seiden","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib49","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: The Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib50","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-0327(90)90009-W","article-title":"The Benzodiazepine Withdrawal Symptom Questionnaire","volume":"19","author":"Tyrer","year":"1990","journal-title":"J Affect Disord"},{"key":"10.1016\/j.clinthera.2006.10.016_bib51","first-page":"A163","article-title":"Double-blind, single-dose, two-way crossover study of ramel teon in subjects with mild to moderate obstructive sleep apnea","volume":"28","author":"Sainati","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib52","first-page":"A162","article-title":"Double-blind, placebocontrolled, two-way crossover study of ramelteon in subjects with mild to moderate chronic obstructive pulmonary disease (COPD)","volume":"28","author":"Sainati","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib53","first-page":"1210","article-title":"Phase 1 study to evaluate the shortterm effects of ramelteon (TAK-375) on endocrine function in healthy adult subjects","volume":"44","author":"Tolbert","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2006.10.016_bib54","first-page":"A44","article-title":"Ramelteon and triazolam in humans: Behavioral effects and abuse potential","volume":"28","author":"Griffiths","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib55","series-title":"Lexi-Comp (Lexi-Companion Guides) [CD-ROM]. Version 2.4.060323","year":"2005"},{"key":"10.1016\/j.clinthera.2006.10.016_bib56","first-page":"A48","article-title":"Effects of multiple doses of fluoxetine on the systemic exposure of a single dose of ramelteon (TAK-375) in healthy adults","volume":"27","author":"Sainati","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib57","first-page":"A53","article-title":"Effects of fluconazole and ketoconazole on the pharmacokinetics of ramelteon (TAK-375) in normal healthy male and female subjects","volume":"27","author":"Karim","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib58","first-page":"A45","article-title":"Open-label assessment of the pharmacokineticsand pharmacodynamics of warfarin in the presence of multiple doses of ramelteon in healthy adults","volume":"28","author":"Karim","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib59","first-page":"A48","article-title":"Two-period crossover study to assess the drug interaction between ramelteon (TAK-375) and theophylline in healthy adults","volume":"27","author":"Tolbert","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib60","first-page":"A46","article-title":"Study to assess the steady-state drug-drug interaction of omeprazole with ramelteon in healthy adults","volume":"28","author":"Karim","year":"2005","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib61","first-page":"A50","article-title":"Study to assess drug interaction between ramelteon (TAK-375) and dextromethorphan in healthy adults","volume":"27","author":"Tolbert","year":"2004","journal-title":"Sleep"},{"key":"10.1016\/j.clinthera.2006.10.016_bib62","first-page":"A47","article-title":"The effect of multiple doses of ramelteon (TAK-375) on the single dose pharmacokinetic profile of midazolam in healthy adult subjects","volume":"27","author":"Karim","year":"2004","journal-title":"Sleep"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806002566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T18:53:45Z","timestamp":1555959225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806002566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0149291806002566"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.10.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}